April 29, 2016 / 12:32 PM / 2 years ago

BRIEF-Valeant Pharmaceuticals restates Q4 results after review

April 29 (Reuters) - Valeant Pharmaceuticals

* Restates q4 results after review; now says q4 gaap loss per share $1.12; co on march 15 reported q4 gaap loss per share of $0.98

* Majority of q4 restatement impact attributed to adjustments relating to deferral of addyi revenue, adjustments to returns reserve of xifaxan

* Q4 restatement impact also attributed to including increased professional service fees and intellectual property related adjustments

* As a result of ongoing analysis and review, reports q4 adjusted earnings per share $1.55; co on march 15 reported q4 adjusted earnings per share of $2.50 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below